Our employees, partners, and investors are committed to IONIQ Science’s Mission to save lives through early cancer detection.
Our
Mr. Bauer joined IONIQ Sciences in September 2018 as a Director and shortly thereafter was appointed to the role of CEO. Mr. Bauer has focused his professional endeavors on the medtech industry and is passionate about healthcare innovation. In 2012, he acquired BurnFree Products, and led the team to expand BurnFree distribution to 58 countries before a successful exit in 2016. Mr. Bauer also currently serves as the CEO of Seek Labs, trustee of The Oliver Fund (a non-profit he co-founded with his wife), Chairman of the BioUtah Salt Lake City (SLC) Biotech Initiative Advisory Committee, Vice Chairman of BioHive (branding initiative for Utah's fast growing life science community), and previously served as an adjunct professor of entrepreneurship at Ensign College. He holds a BS in Economics from the University of Utah, and an MBA from Boise State University.
Jared Bauer, MBACEO, Director 
Mr. Garff joined IONIQ Sciences as the Chief Operating Officer in June 2009. At IONIQ, he obtained US FDA Breakthrough Device Designation and European regulatory approval (CE Mark) for the ProLung Test, organized and operates manufacturing, acquired clinical sites at premier cancer hospitals, and designed and implemented a certified ISO 13485 quality management system. Currently, he oversees IONIQ's product development, manufacturing, clinical studies, regulatory affairs, FDA submissions, quality audits, data analysis, and patents. Prior to IONIQ, he was involved with the Pierre Lassonde Entrepreneur Center where he served as a Director. While there he helped launch several biomedical companies. He holds a BS in Business Finance and an MBA from the University of Utah.
Michael Garff, MBACOO, Director 
Mr. Robertson joined IONIQ Sciences in July 2017 and is focused on identifying mutually beneficial strategic partnerships, establishing and strengthening relationships with sales distribution partners, gaining reimbursement and utilizing the IONIQ ProLung Test CE mark. Over the course of more than 20 years in the global medical device or medtech industry, he has held upstream and downstream marketing positions of increasing responsibility, been publicly recognized with marketing awards and launched 15 medical devices. He brings an invaluable professional perspective and organizational savvy from his tenure with smaller medical device manufacturers (Utah Medical Products and Megadyne now J&J Ethicon) to some of the largest (Covidien now Medtronic, Becton Dickinson and CR Bard). He holds a Bachelor of Science in Marketing from the University of Utah. In particular, Mr. Robertson has a proven track record of profitably delivering what health care providers and patients want.
Andy RobertsonVP Business Development 
Mr. Rex Chin-Wei Yung, MD, FCCP, has been with IONIQ since 2017. As the Chief Medical Officer, he leads the evaluation of opportunities to expand our underlying science and indications through his expertise in translational research of lung cancer biomarkers and early cancer detection through imaging and bronchoscopy. Previously, Dr. Yung was the Chief Scientific Officer at IONIQ. Previous to that, Dr. Yung was the Director of Pulmonary Oncology and Director of Bronchoscopy at Johns Hopkins University School of Medicine (JHU). Dr. Yung remains an adjunct faculty in the Department of Oncology at JHU. Dr. Yung is a fellow of the American College of Chest Physicians. He is board certified in Internal Medicine, Pulmonary and Critical Care Medicine and has served on the executive and editorial boards of the American Association of Bronchology and Interventional Pulmonology and Journal of Bronchology and Interventional Pulmonology. Dr. Yung earned a Bachelor of Arts from Harvard University and his MD from the University of California at Los Angeles (UCLA).
Dr. Rex YungChief Medical Officer 
Mr. Brimhall joined IONIQ in October 2019 as the Director of R&D and is focused on identifying areas of opportunity for our non-invasive Electrical Impedance Analytics (EIA) technology and advancing our new product development pipeline. He has received numerous awards the years, including 35 issued patents, multiple design awards and numerous grant and contract awards from the NIH, DOD, NSF and NASA. He has 30 plus years of R&D leadership in the global medical device industry (Sonic Innovations, Varian Medical Systems and most recently BioMerieux) and global experience in the USA, Europe and China. He received a BS degree in Mechanical Engineering from Brigham Young University with post graduate studies at the University of Utah in Electrical Engineering.
Owen BrimhallDirector R&D 
Our Team
Natasha Andreasen
Clinical Coordinator
Facundo Bianchetti
Clinical Research Scientist
Kyle Larsen, PhD
Research Scientist
Preston Goates
Business Analyst
Open Position
Statistician scientist
Open Position
Bioimpedance Research Scientist
Our Scientific
Advisory Committee
Ørjan G. Martinsen, PhD
World-Renowned Bioimpedance Expert
Benjamin Sanchez, PhD
World-Renowned Bioimpedance Expert
- More than 160 peer-reviewed scientific papers to his credit in addition to authoring and contributing to multiple textbooks
- Twenty years and counting at the University of Oslo where he is currently the Head of Electronics Research Section in the Department of Physics
- Editor-in-Chief and co-founder of the Journal of Electrical Bioimpedance
- Past President of the International Society for Electrical Bioimpedance (ISEBI)
- Invited to speak as keynote speaker at 24 international conferences
- Nearly 60 publications to his credit
- Most recently spent six years at Harvard Medical School’s Department of Neurology and is now at the University of Utah’s Department of Electrical and Computer Engineering
- 2018 Chairman of the Symposium on Recent Innovations and New Health-related Applications of Electrical Bioimpedance, 2018 Program Committee Member for the 11th Annual Conference on Bioelectromagnetism and 2016 Chairman of International Conference on Electrical Bioimpedance
Benjamin Haibe-Kains, PhD
World-Renowned Bioinformatics and Computational Research Expert
- 200 peer-reviewed scientific papers to his credit, including 50 (co-)Senior Responsible Author publications
- Currently Senior Scientist at the Princess Margaret Cancer Centre, Associate Professor in the Medical Biophysics department of the University of Toronto and the Canada Research Chair in Computational Pharmacogenomics
- Formerly at Dana Farber Cancer Institute and Harvard School of Public Health
- Co-Chair and Member of numerous Internal Committees at Princess Margaret Cancer Centre and External Committees
Our Medical
Advisory Committee
Raphael E. Pollock, MD, PhD, FACS
Award-winning, surgical oncologist and physician-researcher
Dr. Rex Chin-Wei Yung, MD, FCCP
IONIQ Chief Medical Officer, pulmonologist and physician-researcher
- Director of The Ohio State University Comprehensive Cancer Center and Kathleen Wellenreiter Klotz Chair in Cancer Research both at (OSUCCC)
- Formerly Surgeon in Chief at both The James Cancer Hospita and Solove Research Institute at The Ohio State University Health System
- Professor Emeritus in the Department of Surgical Oncology at MD Anderson Cancer Center
- Distinguished Member of Graduate School of Biomedical Sciences at the University of Texas Health Sciences System
- Co-authored more than 21 books, 400 original research and review articles
- Adjunct faculty in Department of Oncology at Johns Hopkins University School of Medicine
- Formerly Director of Pulmonology Oncology and Director of Bronchoscopy at Johns Hopkins University School of Medicine
- Lead physician investigator for ProLung Test PL-204 clinical trial results published in Journal of Thoracic Oncology (2012)
- Served on the executive and editorial boards of the American Association of Bronchology and Interventional Pulmonology and Journal of Bronchology and Interventional Pulmonology
"Great ambition and conquest without contribution is without significance."
The Emperor’s Club, 2002
Join Our Team
We are looking for like-minded people who are committed to the science of early cancer detection.
We are looking for team members with expertise in cutting-edge cancer research, development, artificial intelligence (AI) and machine learning, clinical trial management, early cancer detection and medtech commercialization. Help us scale our technology from a lung cancer test “today” and a breast cancer test “tomorrow” to an annual preventative health screen for multiple cancers in the future.
- Tremendous opportunity exists as we rapidly expand
- Healthcare, company-paid holidays and paid time off (PTO)
- Paid time off for community service
- 401 (K) available
- Fun, flexible start-up culture